Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.02
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-3.3M · quality 40.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.9%
↓Gross Margin
61.3%
↑Debt/Equity
5.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
—
FCF margin
-35.1%
FCF / Net income
2.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.4M · net income $-1.3M · FCF $-3.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.4M | $9.4M | $5.6M | $6.7M | $7.1M |
| Net Income | $-1.3M | $-1.3M | $-5.5M | $-1.1M | $-12.7M |
| EBITDA | $-987074.00 | $-987074.00 | $-3.1M | $-1.4M | $-10.2M |
| EPS | -0.00 | -0.00 | — | -0.00 | -0.07 |
| Gross Margin | 61.3% | 61.3% | 76.4% | 74.9% | 10.2% |
| Operating Margin | -25.3% | -25.3% | -88.2% | -36.3% | -117.9% |
| Net Margin | -13.6% | -13.6% | -98.1% | -16.4% | -178.2% |
| Balance Sheet | |||||
| Debt/Equity | 5.41 | 5.41 | -3.80 | 0.46 | 0.15 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.3M | $-3.3M | $-3.5M | $-803465.00 | $-3.1M |
| Returns | |||||
| ROE | -66.9% | -66.9% | 264.5% | -14.5% | -58.0% |
| Valuation | |||||
| P/B | 4.76 | 4.76 | — | 0.96 | 0.21 |
| Growth & Yield | |||||
| Revenue Growth | 67.7% | 67.7% | -15.8% | -6.5% | — |
| EPS Growth | — | — | — | 94.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -0.00
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.